#IRD Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026

#IRD Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
#IRD Opus Genetics to Present at the Chardan Annual Healthcare Conference
Quote of the day.
The #IRD is a weapon of wealth and business theft and is destroying our real, #productive, #economy.
Promoting monopolies.
They are so brain dead they don't see that people who operate on low profits are helping others to produce, and a rising tide floats all taxpayers.
#nzpol
đ $IRD 10-Q â what changed
MD&A now says: "Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion of our financial condition and results of operations should be read in conjunction with the unaudited financial statements and notes included in
đŽ $IRD â Foundation Fighting Blindness, Inc., Director
SOLD: 556,000 shares @ $4.96
Total: $2.8M
Filed Sep 29, 2026 · 8:00pm ET
đ History & trend â https://www.formdelta.com/ticker/IRD
Nanoscope Therapeutics Advances MOGENRYÂź for Inherited Retinal Dystrophies in Japan with Priority Review #Japan #Tokyo #Nanoscope #MOGENRYÂź #IRD
Great analysis of the shocking #IRD and #InsolvencyLaw #BusinessClosures
The most valuable businesses run at very low profit
because their proprietors want to help, not extort people.
They actually need to be PROTECTED from scammers, not closed downâmonopolies.
www.youtube.com/watch?v=rGwj...
#nzpol
Fusion #IRD #CNRS : les spĂ©cificitĂ©s de lâIRD qui seraient perdues Ă la suite du projet de rĂ©organisation
https://theconversation.com/fusion-ird-cnrs-les-specificites-de-lird-qui-seraient-perdues-a-la-suite-du-projet-de-reorganisation-289436
Les donnĂ©es publiques montrent que lâIRD cible le [âŠ]
SEAS Guyane recherche un·e Géomaticien·ne cartographe (VSC)
#emploi #recrutement #jeRecrute #job #VSC
#géomatique #télédétection #satellite
#IRD #UMREspaceDev #Guyane #SEASGuyane
đš JUST IN: $IRD
Opus Genetics reports positive Cohort 1 data for OPGx-BEST1; FDA aligns on pivotal endpoint